TGA grants provisional determination to AstraZeneca for COVID-19 prophylaxis and treatment, tixagevimab and cilgavimab (Evusheld)

TGA

4 January 2022 - On 4 January 2022, the TGA granted a further provisional determination to AstraZeneca in relation to the COVID-19 treatment tixagevimab and cilgavimab (Evusheld), for the prevention and treatment of COVID-19 in adolescents and adults aged 12 years and older.

The original determination of 4 November 2021 was for prevention in adults 18 years and older. This new determination now includes prevention and treatment of COVID-19 in individuals aged 12 years and older.

Read TGA News

Michael Wonder

Posted by:

Michael Wonder